Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioArctic, Audiocast, Q2'26

By Inderes8/26/2026, 7:30 AM
BioArctic

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Gunilla Osswald
00:01 - 07:02

Thank you so much, good morning, and welcome to BioArctic's presentation for the second quarter of 2026. Leqembi continues to progress well with new approvals and launches, and BioArctic has signed additional strategic partnerships. And we will talk more about this in today's webcast. Next slide, please. BioArctic is listed on Nasdaq Stockholm Large Cap. And this is our disclaimer. Next slide please. I am Gunilla Osswald, the CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Löf, our Chief R&D Officer, Johanna Fälting, and our Chief Commercial Officer, Anna-Kaija Grönblad. Next slide please. I will start our presentation by giving some key highlights. Next slide please. BioArctic is among world leaders in two different areas. The first one is regarding highly selective antibodies where we are innovative and we are generating highly selective antibodies targeting aggregated misfolded forms of toxic proteins. And here we have the front-runner, Leqembi. And we also have projects targeting alpha-synuclein and TDP-43, for example. The second area is when we are utilizing our BrainTransporter platform in an innovative and differentiated way to deliver antibodies. And I also want to highlight that we are broadening the platform to enable more efficient transportation into the brain of other modalities with innovative approaches, and this could be utilized for enzymes and genetic medicines like ASOs and siRNA. So a lot of new innovation is coming from BioArctic. Next slide please. We are already delivering on our 2030 ambitions, and they are in four different areas. The first one is regarding Leqembi to establish it as a standard treatment for Alzheimer's disease. And the Leqembi demand shows steady growth for more patients on a global level. Sales are progressing in line with our partner Eisai's guidance. A true highlight during the summer was the FDA approval of Leqembi, the subcutaneous formulation with an autoinjector. We received the approval from the FDA on July 13th, and the US launch started this week. This means that there is an increased convenience for the patients, as they have the possibility to get the treatment at home instead of going to an infusion center. So I think it looks really bright also for further approvals and implementation of blood-based biomarkers, which will also simplify the diagnosis for patients. So these two aspects, the subcutaneous formulation, together with the blood-based biomarkers for diagnosis, are important for patients and for healthcare, and are less costly for society and can lead to a broader uptake on the market. The second area is with regard to a balanced and broader pipeline with projects in all stages of development. And here I want to highlight Exidavnemab, our alpha-synuclein project, which is in phase 2a in both Parkinson's disease and Multiple System Atrophy. We had a planned safety review during this summer, and it was concluded that Exidavnemab showed a favorable safety profile, which supports progression into phase 2b, which is currently in planning. The other alpha-synuclein follow-up compound, called BAN2238, is a follow-up compound to Exidavnemab with BrainTransporter, and here we selected a candidate drug late last year and the IND-enabling activities are progressing really well and the pipeline overall continues to expand and we have added new projects. For example, the ones due to new partnerships. The third area is to have additional successful global partnerships, and we are very pleased with our new license agreement and collaboration with Eli Lilly, as well as our previous collaborations together with Bristol Myers Squibb and Novartis, and, of course, our long-term partner, Eisai. Eisai and all these partners are working on several generations using different approaches. Our latest research collaboration with Mesenkia, a small Swedish biotech company, opens up utilization of our BrainTransporter in a new area, oncology, where better penetration into the brain is wanted. And here, we are focusing to start with on Glioblastoma. I think it's great to see the continued strong interest in our BrainTransporter technology, as well as in our proprietary programs. The fourth area is that our aim is to be profitable and have recurring dividends in the future. We were highly profitable last year, and our strong financial position allows us to continue to invest heavily in our business, as well as giving dividends to our shareholders. We have a strong financial position with about 2 billion Swedish kronor in cash at the end of the second quarter, and this is even without the upfront payment from Eli Lilly of 30 million USD. And we expect to be profitable this year. Next slide please. Partnerships are a cornerstone in our business model and the key component behind our success. Our focus has been on big pharma and different business models. So we have two different business models here. The first category we can see is Eisai, AbbVie, and Bristol Myers Squibb, where they have done in-license agreements on innovative BioArctic-developed programs. The second category is Novartis and Eli Lilly, who are utilizing BioArctic as a platform company. So they bring their compounds to BioArctic. We re-engineer the compounds and build in our BrainTransporter technology into new compounds, and we then check the transferrin receptor functionality and then hand it back to the partner who drives and finances the program further. I also want to add a new addition to our business model, which is what we are doing with Mesenkia. I think this represents another category that we are now starting with a small research collaboration, and that could also lead to future business. Next slide please. Now I hand over to our Chief R&D Officer, Johanna Fälting.

Johanna Fälting
07:02 - 17:15

Thank you so much, Gunilla. Next slide please. So our R&D portfolio continues to advance, as Gunilla has described. And this is really built on two complementary platforms: the antibodies and the BrainTransporter platform. A balanced mix of funded partnerships with Eisai, BMS, Novartis, and Eli Lilly, together with proprietary programs, provides both external validation and significant long-term value creation opportunities in the portfolio. All BrainTransporter collaborations are progressing well, and during the quarter, we have further strengthened the platform through two new collaborations: the Eli Lilly partnership, which represents a major validation by a leading neuroscience company and highlights the platform's broad potential in the CNS. And then we have the Mesenkia collaboration that marks our first step into oncology, expanding the BrainTransporter platform beyond neurodegenerative diseases and broadening its future application potential. So overall, we continue to advance the diverse, increasingly partnered, validated pipeline with expanding scientific and commercial potential, both for our antibody and our BrainTransporter platform. Next slide please. So, taking a closer look at our alpha-synuclein portfolio, it is moving forward and expanding. So for Exidavnemab during the quarter, we have evaluated the safety data from the phase two AXIS study of Exidavnemab in both Parkinson's disease and Multiple System Atrophy. The results confirmed a favorable safety profile of the antibody, which is an important milestone for the program. This data will provide a strong foundation for the next step of development, and we are currently planning for phase 2B studies in both Multiple System Atrophy and Parkinson's disease-related dementia, with the ambition to initiate these studies next year. Exidavnemab remains the most advanced alpha-synuclein-targeting program in our pipeline and addresses a significant unmet medical need in neurodegenerative diseases. And for BAN2238, our BrainTransporter-enabled alpha-synuclein antibody. We continue to make progress with the IND-enabling activities during the quarter for BAN2238. It combines our disease expertise in alpha-synuclein biology with the BrainTransporter technology, which is designed to enhance the antibody's delivery across the blood-brain barrier. And this program is progressing according to plan, and we are currently expecting to initiate clinical development next year. So together, Exidavnemab and BAN2238 represent a complementary strategy combining the most advanced clinical stage asset with a next-generation BrainTransporter-enabling program targeting the same underlying disease biology. So next slide, please. So, one of the quarter's key highlights for us was really the new BrainTransporter collaboration with Eli Lilly. Lilly's selection of the BrainTransporter for next-generation CNS therapies provides a strong validation from a leading pharmaceutical company and reinforces the importance of efficient blood-brain delivery for CNS drug development. And this collaboration, of course, expands the potential application of the BrainTransporter beyond our internal programs. And it combines BioArctic's neuroscience expertise with Eli Lilly's global development capabilities, further strengthening the platform for long-term strategic and commercial value. The Mesenkia collaboration in oncology marks BioArctic's entry into the oncology target space and expands the application of the BrainTransporter beyond neurodegenerative diseases. And the main focus here is glioblastoma, which is a highly aggressive brain cancer with significant unmet medical need. And together with Mesenkia, we are now evaluating a novel approach by combining the BrainTransporter with Mesenkia's HVEM-targeting antibody, enhancing drug delivery to the brain and the capability to reach tumor cells associated with recurrence and treatment resistance. The initial goal is to generate a drug candidate and establish a preclinical proof of concept for the program, further demonstrating the versatility of the BrainTransporter platform. So taken together, the Eli Lilly and Mesenkia collaborations highlight the broad potential of the BrainTransporter. Lilly validates the platform in neurodegeneration, while Mesenkia extends. Extends its application into oncology, demonstrating its versatility across multiple disease areas. So, next slide, please. And then I will hand over to our Chief Commercial Officer, Anna-Kaija Grönblad. Sorry. Thank you, Johanna. So let me go back to Leqembi and the global rollout of the subcutaneous treatment, as I already mentioned. This is clearly an important step in expanding patient access and further strengthening our continued growth. So in the US, the FDA approval came in July for the Leqembi Iqlik initiation treatment. It is available as of this week. This will clearly increase momentum as we move into the second half of 2026. And this will allow people the option to inject the drug themselves instead of going to the hospitals. So they can do this at home for the whole course of treatment. And so, without having to come to the clinic for the time-consuming and more invasive infusions. This change is really expected to broaden uptake, especially for people who live far from the clinics or travel frequently. Looking at other benchmarks in the industry, we believe the uptake in the US will happen gradually as the coverage will broaden at different time points, with an expected shift potentially coming in the beginning of 2027. And we hope that the Medicare Part D coverage for both the initiation and maintenance can begin in January 2027. But we believe it will clearly be a commercial game changer and an advantage versus the competition in Japan. We expect the approval soon in this third quarter of 2026 and reimbursement a bit later, expected to follow in the fourth quarter. And in China. The product is currently under priority review, and we expect the approval in the first half of 2027. Importantly, data presented in July this summer at the AAIC Congress in London showed that the efficacy and the safety of the subcutaneous administration are comparable to the IV treatment. So it clearly supports the potential of this more convenient treatment option. Eisai also continues to make progress across other international markets. So during the second quarter, Leqembi was launched in Australia, Belgium, Brazil and India. And at the same time, market interest is unfortunately generally slower in Europe. The process continues to improve patient access across Europe. Here, the less frequent IV maintenance dosing is currently under EMA regulatory review, and if approved, this could not only enhance the convenience of continuous treatment but also facilitate access discussions in some other countries in Europe. In the UK, commercial discussions between Eisai and the NHS England are ongoing, and we are seeing some encouraging interest from several private clinics in the Nordic countries. And as we progress, we are also continuing discussions for broader public reimbursement. So overall, we are very pleased with the progress, and together with the uptake and usage of blood-based biomarkers, we see significant opportunities to further expand patient access and growth. If you go to the next slide. So coming back to the AD Congress in London this summer. Several speakers showed data on how the drug is performing in the real world. Here I am highlighting a US post-market study called LEADER, which now includes 16 clinical sites across the country. Data were presented for about 400 patients from 13 sites, and after an average of 17 months of Leqembi use, approximately 83% had not progressed to more advanced disease as assessed by a clinician. So of these, 76% remained at the same disease stage and 6.5% improved for a bit more than 200 people who have reached two years of treatment. The data are similar, 74% were stable and 9% improved. Among the more than 200 patients that had been on treatment for more than 18 months, almost 80% transitioned to maintenance treatment either with Leqembi IV or subcutaneous Leqembi. So finally, safety observations in this real-world study were consistent with the FDA-approved label. We are looking forward to the next data cut. Approximately 600 patients will likely be presented in November at the CTAD Congress. So with that, I hand over to Anders, our CFO.

Anders Martin-Löf
17:15 - 24:36

Thank you, Anna. And if we then turn to the Leqembi numbers, we can see that the Leqembi growth continues. The global Q2 sales were ¥29.3 billion, or roughly $184 million, representing a healthy 12% increase from the first quarter, or 27% increase from the second quarter of 2025. If we translate that into our royalties, you see that our royalties grew by 12% to 179.4 million Swedish kronor in the second quarter. It does not look as fantastic if you compare it with the second quarter of 2025. But as you remember, there was a very large stockpiling effect in the second quarter of 2025. If you remove that one-time effect, the annual growth would have been roughly 43% in terms of royalties. So, all in all, on a global scale, the growth looks really good. But then turning to the US, the growth there, 13% going to $27 million in the quarter, is now mainly driven by simplified diagnosis. And you should understand that there is a very tough competitive situation right now in the US in the period that ended. The Iqlik launch that happened earlier this week is going to be really exciting to follow. This has the potential to drive the royalties from Leqembi in a number of ways. First of all, I mentioned that the uptake of patients is likely going to increase due to the fact that it is so much easier for patients to access the therapy this way. On top of that, Leqembi should be able to generate a larger share of new patients, as it will be the only drug that is available in the subcutaneous formulation. And the third factor is that since this is a much more efficient way of delivering these therapeutics, a larger share will end up with the pharmaceutical part of the treatment cost. So the revenue per patient is likely to go up as well. So, all in all, this will be a very important factor for the royalties in the future. And it will be very exciting to follow. In China, we also saw very healthy growth, with sales going up to 30 million. Here we will also most likely see the introduction of the subcutaneous version in the beginning of 2027. We are also seeing broader insurance coverage. Eisai communicated that it will start to come into place in the fourth quarter of this year. Also a very intriguing development. Japan was tough this quarter. It was flat from the first quarter. Roughly $38 million in sales. And it seems, based on presentations that we saw at the large conferences this summer, that the issue of capacity for infusions in Japan has been tougher there than in other markets. So it would be very important now that we expect to see the subcutaneous version come out also in Japan. We are expecting approval in the third quarter of this year and the reimbursement and launch towards the end of this year. All in all, I think things are going fairly well. But the subcutaneous introduction will really have an impact here, even though it may not come directly, but gradually, this will have a very large impact on the royalties. The EU has been slow. We have talked about that in previous presentations and it is still slow, so we will not dwell on that too much. All in all, as I reiterated their forecast of ¥143.5 billion in their fiscal year 2026, that is roughly $900 million of sales this year. And that corresponds to roughly 880 million Swedish krona in royalties during the time period. If we then turn to our numbers starting from the left, you see our net revenues that amounted to 248 million in the second quarter. That looks like we are shrinking from the second quarter of 2025. But this is all due to the fact that there was a milestone of 223 million in 2025, and there were no milestones that were paid in the second quarter of this year. The underlying recurring revenues continue to increase. The royalties were roughly 179 million and we also had co-promotion revenues. So we are approaching 200 million in recurring revenues every quarter, which is very healthy. We also have some revenues from our collaborations. We entered into a collaboration with Novartis last year where we recognized 51 million from that upfront payment in the second quarter. And as already mentioned, we also entered into a collaboration with Eli Lilly in the second quarter of this year. None of that was recognized in the second quarter. We will start to recognize that from the third quarter. And we expect that roughly 40% of the $30 million will be recognized during the remainder of 2026. Turning then to our costs, they continue to increase. Our costs were 232 million in the second quarter, up from 193 million a year ago. And this is all due to the fact that we are investing more and more in our project portfolio in preparations for our other exciting trials with Exidavnemab. We reiterate here that for the full year 2026, the operating costs are expected to increase by 40% to 60% compared to the year before. So if anything, I would say in the low range of that span, but we reiterate roughly 40 to 60%. As you see on the right-hand graph, we were not making a profit in the second quarter. But all in all, in the first half of the year, we made a profit of 179 million. And we still expect to be profitable for the full year if we then turn to the net result. You see that was slightly negative due to an impact of financial net and tax. The cash flow was very positive, much stronger than the operating profit. That is due to the fact that the Eisai €20 million sales milestone was paid in May, and then cash and cash equivalents were roughly 2 billion at the end of the second quarter. And that is despite us paying a dividend of 177 million SEK in June. And this does not include the $30 million upfront payment that was paid in July. So at the end of July, we had over 2.3 billion in cash. So all in all, our position remains extremely solid with plenty of room to keep investing in our R&D portfolio. With that, I hand over back to Gunilla.

Gunilla Osswald
24:36 - 28:03

Thank you so much. So we are coming towards the end of today's presentation with some upcoming news flow and some closing remarks. Next slide please. So if we look at the second quarter, I think it was great to see more patients getting access to Leqembi around the globe. Also in smaller scale in the Nordics so far through the private clinics in Finland, and hopefully soon also in other Nordic countries. Eisai is driving continued regulatory processes on Leqembi in a great way, and the Iqlik, the subcutaneous version with an autoinjector, was recently approved and launched. Now also for initiation in the US, and later this year, we expect responses from authorities in Japan and in China next year. We also heard about continued impressive results from real-world usage. When we were at the AAIC Congress in London in July, as I alluded to, and also for subcutaneous data, we are looking forward to the next big Alzheimer's disease congress called Clinical Trials in Alzheimer's Disease (CTAD), which is in Boston in November, where we also expect more presentations around Leqembi and Exidavnemab. The phase two. The study results are expected later this year. We heard some really important safety data that was coming during the summer, but the full study is expected to read out late this year, and we are preparing for starting phase two. Maybe next year we will communicate on further potential partnership milestones when that is relevant. When that is relevant. Next slide please. So some key takeaways from today's presentation. I think BioArctic shows continued growth and we have made great progress both on Leqembi as well as the rest of our portfolio and the BrainTransporter technology. As I said, we are delivering on our 2030 ambitions already in a great way. Leqembi is well on track to become an established treatment in Alzheimer's disease, and sales continue to show increasing global demand. The subcutaneous autoinjector Leqembi has now been launched in the US, also for initiation treatment, which is a major milestone. Our business development efforts continue to deliver, and we have just concluded a landmark deal with Eli Lilly using our BrainTransporter technology, and we have expanded our product portfolio also into oncology by the new research collaboration with Mesenkia, also utilizing our BrainTransporter technology. And last but not least, we have a very strong financial position, which was about 2 billion Swedish kronor in cash at the end of June. And this is after the dividend of two Swedish kronor per share, and before receiving the upfront payment of 30 million USD from Eli Lilly, and we expect a positive result this year. So, all in all, I think BioArctic is exceptionally well positioned for continued growth, and the future looks very bright for BioArctic, bringing hope for many patients. Next slide please. So by that, we say thank you so much for your attention, and we are happy to take some questions.

Operator
28:04 - 28:21

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Joseph Haydn from WR Securities. Please go ahead.

Joseph Haydn
28:22 - 29:06

Good morning. Thanks for taking my questions. Congratulations on the collaboration with Mesenkia. That certainly looks like an exciting application of BrainTransporter. Just wondering if you could give us your thoughts on the timeline to the pre-clinical validation. And then, any details you can give us on additional aspects of the deal: who will be in control of the clinical development? Or are you going to be looking for a partner? And secondly, if I could just ask on Exidavnemab, you stated that you have passed the safety analysis that facilitates phase two. But are you still expecting to be presenting results from the study? Thank you.

Gunilla Osswald
29:10 - 29:14

I am sorry. I had a little difficulty hearing you. The first question was.

Johanna Fälting
29:14 - 29:15

On Mesenkia timelines.

Gunilla Osswald
29:15 - 29:21

Mesenkia. Okay. I thought it was Eli Lilly. Okay, so. Mesenkia. Okay, maybe Johanna would like to address that.

Johanna Fälting
29:21 - 30:01

Thank you, Joseph, for that. Those questions. I can start with the question on Mesenkia. This is a preclinical research collaboration that will validate the target preclinically together with our BrainTransporter platform. So after that, we will continue with discussions on how we should progress this, but I think it is a bit too early to talk about the timelines really and when this kind of program could go into the clinic. This is a first research collaboration where we each have defined responsibilities, and we will perform a pre-clinical evaluation in a disease model to see if the concept works. And then we will go on into further discussions on how to progress if positive.

Gunilla Osswald
30:04 - 30:11

And the second question was with regard to Exidavnemab. Exidavnemab. So, maybe you want to take that also. Johanna.

Johanna Fälting
30:11 - 30:22

Yes. So that was the Exidavnemab study. Yes, our plan is to conclude this study by the end of the year and report the data from it.

Joseph Haydn
30:25 - 30:39

Thank you. And just to follow up on Mesenkia, if I could, are there any other companies looking at that specific target in Glioblastoma? Or is this a completely novel program?

Johanna Fälting
30:41 - 31:25

As far as we know. I think this is a unique target, and that is why we believe it is very interesting. And I think it is also unique. Combining one of these diseases together with the BrainTransporter platform. As far as we know, there are no other programs out there trying to treat glioblastoma with any target. And in combination with the transferrin receptor BrainTransporter platform. So I think that it's a really interesting program, and we really think it's solid and promising. The science behind Mesenkia involves targeting what could be seen as a stem cell for these cancer drugs in an extremely difficult-to-treat patient population and disease.

Joseph Haydn
31:29 - 31:30

Okay. Got it. Thank you.

Gunilla Osswald
31:32 - 31:33

Thank you. Joseph.

Operator
31:35 - 31:39

The next question comes from Max Dorf from Goldman Sachs. Please go ahead.

Max Dorf
31:40 - 32:20

Hi, this is Max for Rajan Sharma. Thank you for taking my questions. I have a few. The first question is about lecanemab. So in your phase two study, did you see any efficacy signal? And when should we expect the results from the phase two study? Second question, how will you prioritize between Exidavnemab and BAN2238? Also, if I can have another question, could you talk about when Eli Lilly will make a decision to move the program forward to clinical development? Thank you very much.

Gunilla Osswald
32:24 - 32:25

Do you want to take it?

Johanna Fälting
32:25 - 33:56

Yeah, absolutely. So if we start with the question on Exidavnemab efficacy from the study, I think that you should remember that this study that we are now concluding is a phase 2a study. It is a small study, and the primary endpoint is safety and tolerability. We are also looking at biomarkers and exploratory endpoints. But I do not think we should get our hopes up too high on that one. Because the study is not powered to look for clinical efficacy. It is not long enough. It's three months. And I believe you need a much longer duration for that. But we are definitely looking into that. But the primary endpoint is safety and tolerability. And in terms of the phase 2b results, I think that we haven't communicated externally on those timelines. We are still looking at the design and planning of this study. And in terms of the prioritization between Exidavnemab and BAN2238. I think a real strength with this portfolio is that there are so many diseases here to treat. Alpha-synuclein is a key component in Parkinson's disease, in Multiple System Atrophy and in DLB, and potentially also in some other diseases. I mean, we see a lot of co-pathology also with Alzheimer's disease. So my hope would be that we don't need to prioritize between these two, that we can actually position them for different diseases depending on how they span out. So I think that there is a real strength in having two different options that might be able to be positioned for two different diseases.

Gunilla Osswald
33:59 - 34:07

And the third question was with regard to Eli Lilly and the collaboration there. We do not disclose details on that.

Max Dorf
34:09 - 34:10

Got it. Thank you very much.

Gunilla Osswald
34:11 - 34:11

Thank you.

Operator
34:14 - 34:26

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Matthias Haggblom from Nordea. Please go ahead.

Matthias Haggblom
34:28 - 35:18

Yeah. Thanks so much. Thanks for taking my question. I have two questions, please. So firstly on Exidavnemab, we have now confirmed a favorable safety profile from the ongoing Phase 2 testing in Parkinson's and MSA patients. Sometimes the pushback around this asset comes back to the fact that it is now roughly four years or somewhat more than four years since it was handed back to you. So I guess the question is, was there a point in time where there was a chance to use, perhaps based on clinical trial design, an opportunity to speed up clinical development and explore the optimal dose? And if not, why? And then secondly, with the draft guidance from the FDA on trial design in January, how is the company thinking about this as a tool across the rest of the portfolio in general terms? Thanks so much.

Gunilla Osswald
35:20 - 36:42

So, should I, or do you want to? You can. Yeah. No. I agree with you that we received the Exidavnemab program back from AbbVie in 2022. And when they had done two phase one studies, both of those studies showed excellent data with regard to safety, tolerability, and pharmacokinetics. So the next thing that needed to be done was of course to look at multiple dosing. And we did that then in Parkinson's patients. And we also had the MSA patients. So we have expanded this and we see more opportunities for further indications as well. So of course, you are right that there is a lot of interest in different kinds of innovative clinical design models. And with the Bayesian statistics. And we did utilize that for Leqembi. So far for Exidavnemab, we have done a more traditional design and are taking it a bit more stepwise here. So, I think a Bayesian design is really interesting when it is the right thing. But so far for Exidavnemab, we have utilized traditional design.

Matthias Haggblom
36:46 - 36:53

And do you have any general thoughts around the clinical design for the rest of the portfolio, or what the draft guidance updated in January may possibly mean?

Gunilla Osswald
36:54 - 37:35

Yes, I think it is definitely something which is important and will continue to be important. And I think how it was utilized for Leqembi is really also seen as a role model. That phase 2b study with this adaptive design and with Bayesian design, I think it was really innovative and also came with really good results. The dose used in the Phase 3 study was selected based on a more traditional design. So I think it is important sometimes to use traditional design, but also in the future, of course, to look at adaptive designs and Bayesian design.

Operator
37:42 - 37:50

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Oskar Bosson
37:51 - 38:07

Thank you so much. We have a couple of written questions here. We will start with one from Mr. Tallinn. He is asking about the research collaboration that we have ongoing for BAN2238 with Eisai. If there are any updates we can give there.

Gunilla Osswald
38:08 - 38:29

I am sorry to disappoint you. When it comes to different collaborations and discussions with partners, we cannot disclose details. We can just say that everything looks really great regarding BAN2802 and that we are in discussions with Eisai, but we cannot disclose anything more at this moment.

Oskar Bosson
38:30 - 38:48

Thank you. And then another question from Mr. Balder. And he is asking about the Bristol Myers Squibb collaboration. He is asking if it is still in the preclinical phase and when it can be expected to enter patients.

Gunilla Osswald
38:48 - 39:01

So we can say that I think we have a really great collaboration also with Bristol Myers Squibb. And again, we cannot disclose details of their program. Sorry.

Oskar Bosson
39:02 - 39:22

Great. Thank you, Gunilla. I think there are no more people in the queue, and there are no more written questions either. If you have any follow-up questions, you are obviously always welcome to give us a call or send us an email, but I think that concludes today's call. We look forward to seeing you again in three months.

Gunilla Osswald
39:23 - 39:24

Thank you so much. Have a great day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…